Home › Compare › GKTRF vs ABBV
GKTRF yields 1.82% · ABBV yields 3.09%● Live data
📍 GKTRF pulled ahead of the other in Year 4
Combined, GKTRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GKTRF + ABBV for your $10,000?
GEK TERNA Holdings, Real Estate, Construction S.A., together with its subsidiaries, engages in the construction, real estate, mining, electricity, and concession businesses in Greece, the Balkans, the Middle East, Eastern Europe, the United States, and internationally. The company is involved in the construction of motorways, rail networks, buildings, hospitals, museums, industrial facilities, hydroelectric projects, dams, power plants, etc. for public and private sectors; and the financing, management, and commercial operation of concession projects, such as motorways and parking stations. It also develops and operates wind farms, hydroelectric projects, waste treatment and biogas production plants, and photovoltaic parks, as well as develops pumped storage and infrastructure projects. In addition, the company produces 895.3 MW of electric energy and trades in natural gas. Further, it engages in the acquisition, development, and exploitation of real estate properties, including business centers, industrial parks, entertainment parks, residential properties, hotels, etc.; production of quarry products; and exploitation of magnesite quarries. Additionally, the company operates thermal power plants with a total installed capacity of 147 MW and 435 MW in Viotia, Greece. GEK TERNA Holdings, Real Estate, Construction S.A. was formerly known as Ermis Real Estate Constructions Enterprises S.A. The company was founded in 1960 and is headquartered in Athens, Greece.
Full GKTRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.